Eli Lilly and Novo Nordisk Prescription Data Comparison

Below is an interesting article comparing weekly prescriptions for Eli Lilly’s oral agent vs. Novo Nordisk's oral agent. Link and summary included below:

Lilly's obesity pill records modest second week as battle with Novo intensifies

Eli Lilly and Novo Nordisk Prescription Data Comparison:

Foundayo: Weekly prescriptions grew from 1,390 at launch to 3,707 by April 17. *2nd week)

Wegovy Pill: Significantly outpaced Foundayo, jumping from 3,071 in its first four days to , 18,410 by its second week.

This infographic by Kontra Invest Kontra also suggests that NVO is winning the volume battle currently.

Oral Wegovy has clearly been one of the most successful launches of all time. However, it will be interesting to see how this shows up in the numbers of each of these companies because Eli Lilly has continued to impress, whereas Novo has underwhelmed of late.

---

Thank you for reading and see you for the next one!